Back to the program

Topic-Contributed Paper Session

Recent advances and emerging challenges for expedited oncology development program

Wed, Aug 9, 10:30 AM

Liwen WuChair

Biopharmaceutical Section

5 Presentations

To go or not to go in Phase 2/3, a critical question with a unified answer

10:35 AM - 10:55 AM

Cong Chen (Merck & Co., Inc.)

Flexible Seamless 2-in-1 Design with Sample Size Adaptation

10:55 AM - 11:15 AM

Jianchang Lin (Takeda)

Co-authors: Liwen Wu (Takeda Pharmaceuticals)

A Bayesian Nonparametric Model for External Data with Application to Clinical Trials

11:15 AM - 11:35 AM

Yuan Ji (The University of Chicago)

DOME: A Bayesian Dual-criterion Optimal Design for Multi-cohort Expansion cohorts

11:35 AM - 11:55 AM

Ruitao Lin (University of Texas, MD Anderson Cancer Center)

Co-authors: Jinjie Chen (BMS), Rong Liu (BMS), Haolun Shi

Enhancing study efficiency of cancer immunotherapy trials with delayed treatment effect

11:55 AM - 12:15 PM

Zhenzhen Xu (FDA)

↑